Athenex, Inc. (NASDAQ:ATNX) has received a consensus broker rating score of 2.00 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company.

Brokers have set a 1 year consensus target price of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 106 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently commented on the stock. J P Morgan Chase & Co assumed coverage on shares of Athenex in a research note on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price objective for the company. Laidlaw assumed coverage on shares of Athenex in a research note on Tuesday, September 19th. They set a “buy” rating and a $36.00 price objective for the company. Credit Suisse Group assumed coverage on shares of Athenex in a research note on Monday, September 18th. They set an “outperform” rating and a $25.00 price objective for the company. Royal Bank Of Canada assumed coverage on shares of Athenex in a research note on Thursday, September 14th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Deutsche Bank AG assumed coverage on shares of Athenex in a research note on Monday, July 10th. They set a “buy” rating and a $20.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/zacks-athenex-inc-atnx-receives-average-rating-of-buy-from-analysts-2.html.

Hedge funds have recently added to or reduced their stakes in the stock. Laurion Capital Management LP purchased a new stake in Athenex in the second quarter worth about $1,600,000. OxFORD Asset Management LLP purchased a new stake in Athenex in the second quarter worth about $956,000. California Public Employees Retirement System purchased a new stake in Athenex in the second quarter worth about $800,000. Vanguard Group Inc. purchased a new stake in Athenex in the second quarter worth about $800,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Athenex in the second quarter worth about $601,000. 0.88% of the stock is owned by institutional investors.

Athenex (ATNX) opened at 17.13 on Monday. The company’s 50-day moving average price is $17.67 and its 200 day moving average price is $16.82. The company’s market capitalization is $977.49 million. Athenex has a 12 month low of $11.21 and a 12 month high of $20.79.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $4.60 million for the quarter. Analysts forecast that Athenex will post ($2.22) EPS for the current fiscal year.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.